Latest media releases
UBS Warburg Names Meirav Chovav Biotechnology Analyst
UBS Warburg announced today that Meirav Chovav will join the firm as senior biotechnology analyst. Ms. Chovav will be a managing director and will report to Raul Esquivel, director of U.S. Research.
Meirav is a talented, well respected analyst and we are delighted to welcome her to UBS Warburg," said Mr. Esquivel. She further strengthens our commitment to the healthcare sector," Mr. Esquivel added.
Prior to joining UBS Warburg, Ms. Chovav was a senior biotechnology analyst at Credit Suisse First Boston and prior to that at Salomon Smith Barney where she covered the biotechnology sector since 1992. Ms. Chovav holds an MBA from Rensaleer Polytechnic Institute and an MS in molecular biology and a BS in microbiology from the University of Rochester.
Ms. Chovav has ranked on the Institutional Investor "All-America Research Team" in each of the past seven years, and 2001 was ranked number one. She was also recognized as the best stock picker in the biotechnology sector by The Wall Street Journal.
UBS Warburg is a business group of UBS (NYSE: UBS), one of the largest financial services firms in the world with 71,000 employees in more than 40 countries. UBS Warburg is a leader in equities, corporate finance, M&A advisory and financing, financial structuring, fixed income issuance and trading, foreign exchange, derivatives and risk management. The firm is one of four business groups of UBS AG along with UBS PaineWebber, UBS Global Asset Management and UBS Switzerland.
# # #
Inquiries: Amy Rosenberg: +1 212-713-8510 (w) of UBS Warburg
The products, services, information and/or materials contained within these web pages may not be available for residents of certain jurisdictions. Please consult the sales restrictions relating to the products or services in question for further information.
© UBS 1998 - 2014. All rights reserved.